Isracann Biosciences Income Statement

Financials in millions CAD. Fiscal year is June - May.

Millions CAD. Fiscal year is Jun - May.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	May '22 May 31, 2022	May '21 May 31, 2021	May '20 May 31, 2020	May '19 May 31, 2019
Selling, General & Admin	2.39	4.78	11.18	5.27
Operating Expenses	2.43	4.82	11.22	5.32
Operating Income	-2.43	-4.82	-11.22	-5.32
Interest Expense	-	-0.14	-	-
Interest & Investment Income	0.09	0.08	0.14	0.06
Currency Exchange Gain (Loss)	0.01	0.28	-0.29	-
Other Non Operating Income (Expenses)	-0.13	-0.12	-0.39	-0.34
EBT Excluding Unusual Items	-2.46	-4.72	-11.77	-5.6
Merger & Restructuring Charges	-	-	-0.16	-
Gain (Loss) on Sale of Investments	-1.48	-	-	-
Gain (Loss) on Sale of Assets	-	0.25	-	-
Asset Writedown	-	-20.62	-12.06	-
Other Unusual Items	-0.75	-	-	-
Pretax Income	-4.69	-25.09	-23.99	-5.6
Income Tax Expense	-	0.03	-0.07	-
Earnings From Continuing Operations	-4.69	-25.12	-23.92	-5.6
Earnings From Discontinued Operations	-	-0.03	-0.28	-4.3
Net Income	-4.69	-25.16	-24.2	-9.9
Net Income to Common	-4.69	-25.16	-24.2	-9.9
Shares Outstanding (Basic)	148	138	93	38
Shares Outstanding (Diluted)	148	138	93	38
Shares Change (YoY)	6.76%	49.21%	142.09%	-
EPS (Basic)	-0.03	-0.18	-0.26	-0.26
EPS (Diluted)	-0.03	-0.18	-0.26	-0.26
Free Cash Flow	-1.75	-4.24	-10.4	-3.15
Free Cash Flow Per Share	-0.01	-0.03	-0.11	-0.08
EBITDA	-2.39	-4.78	-11.18	-5.27
D&A For EBITDA	0.04	0.04	0.05	0.04
EBIT	-2.43	-4.82	-11.22	-5.32
Advertising Expenses	0.13	1.58	6.73	1.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.